Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer

被引：2
|
作者：
Rezvani, Hamid [1 ]
Ghadyani, Shirin Haghighi Mojtaba [1 ]
Attarian, Hamid [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Tehran, Iran
来源：
UROLOGY JOURNAL | 2012年 / 9卷 / 04期
关键词：
prostatic neoplasms; treatment failure; antineoplastic agents; drug resistance; PHASE-II TRIAL; MITOXANTRONE PLUS PREDNISONE; CLINICAL-TRIALS; WORKING GROUP; DOCETAXEL; ANGIOGENESIS; RECOMMENDATIONS; GUIDELINES; INHIBITOR; REGISTRY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer. Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. Results: Mean age of the participants was 72.7 +/- 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events. Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
引用
收藏
页码：673 / 677
页数：5
相关论文
共 50 条
  • [21] Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer
    Borrega, P
    Velasco, A
    Bolaños, M
    Pérez, MD
    Mel, JR
    Reina, JJ
    Rodríguez-Jaraiz, MA
    Chaves, M
    González-Barón, M
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (01) : 32 - 35
  • [22] Mechanisms leading to the development of hormone-resistant prostate cancer
    Kasper, Susan
    Cookson, Michael S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2006, 33 (02) : 201 - +
  • [23] PROGNOSTIC FACTORS IN HORMONE-RESISTANT PROGRESSING CANCER OF THE PROSTATE
    FOSSA, SD
    DEARNALEY, DP
    LAW, M
    GAD, J
    NEWLING, DWW
    TVETER, K
    ANNALS OF ONCOLOGY, 1992, 3 (05) : 361 - 366
  • [24] Serum chromogranine a and chemotherapy in hormone-resistant prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [25] Management of hormone-resistant prostate cancer: An Australian trial
    Raghavan, D
    Coorey, G
    Rosen, M
    Page, J
    Farebrother, T
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 20 - 23
  • [26] Immunotherapy enhanced by geroprotection: Hormone-resistant prostate cancer
    Lasalvia-Prisco, E. M.
    Dau, C.
    Goldschmidt, P.
    Galmarini, F.
    Vazquez, J.
    Lasalvia-Galante, E. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Residual androgen depending in hormone-resistant prostate cancer
    Fossa, SD
    ACTA ONCOLOGICA, 1997, 36 (01) : 81 - 82
  • [28] Chromogranin-A blood levels in relation to prolactin secretion in hormone-resistant metastatic prostate cancer
    Frontini, L.
    Ardizzoia, A.
    Bignami, A.
    Dapretto, E.
    Lissoni, P.
    Gardani, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 82 - 83
  • [29] A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer
    Galcerán J.C.
    Piulats R.B.
    Martín-Broto J.
    Rey P.M.
    Aligué M.N.
    Santasusana M.D.
    Lanza A.A.
    Molins J.B.
    Colin C.
    Girard A.
    Clinical and Translational Oncology, 2005, 7 (2) : 66 - 73
  • [30] Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer
    Sayin, Meral
    Celenkoglu, Gokhan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (08): : 1026 - 1032
12345